L3VLUP
ProSign in

ESTA · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ESTALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ESTA
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterESTALLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 20201 holders, $9.4m29 holders, $17.3bn
Q1 20212 holders, $24m24 holders, $23.0bn
Q2 20212 holders, $34m24 holders, $27.8bn
Q3 20212 holders, $24m31 holders, $29.9bn
Q4 20211 holders, $21m31 holders, $34.7bn
Q1 20221 holders, $20m24 holders, $35.3bn
Q2 20221 holders, $16m33 holders, $42.7bn
Q3 20222 holders, $19m31 holders, $43.4bn
Q4 20224 holders, $71m31 holders, $46.6bn
Q1 20232 holders, $57m33 holders, $44.3bn
Q2 20231 holders, $19m37 holders, $59.6bn
Q3 20231 holders, $14m44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 20242 holders, $75m41 holders, $95.3bn
Q2 20242 holders, $50m43 holders, $110bn
Q3 20241 holders, $64m45 holders, $107bn
Q4 20241 holders, $88m46 holders, $93.9bn
Q1 20253 holders, $111m42 holders, $98.4bn
Q2 20253 holders, $61m43 holders, $93.2bn
Q3 20253 holders, $54m39 holders, $86.7bn
Q4 20257 holders, $98m41 holders, $123bn
Q1 20264 holders, $14m39 holders, $106bn
Q2 20262 holders, $18m44 holders, $132bn
ESTA

Establishment Labs HLDGS Inc

Holders
2
Reported value
$50m
Buyers
2
Sellers
0

Breadth +2 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ESTA (0)

None.

Only LLY (41)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, and 16 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →